We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
Once-weekly dulaglutide’s effects on blood sugar levels in patients by gender, diabetes duration, and starting HbA1c
AI simplified
Abstract
In a pooled analysis, patients treated with dulaglutide 1.5 mg showed an average reduction in of -1.26% for men and -1.33% for women after 6 months.
- Dulaglutide treatment produced consistent reductions in HbA1c across different gender groups and varying durations of diabetes.
- Patients with a higher baseline HbA1c (≥8.5%) experienced greater reductions in HbA1c compared to those with lower levels (<8.5%).
- Similar trends in reductions were observed in line with HbA1c changes.
- Body weight changes were generally comparable across different durations of diabetes and baseline HbA1c subgroups, with women experiencing slightly more favorable outcomes.
- The incidence and rate of hypoglycaemia were lower in patients with higher baseline HbA1c, although results varied in one specific study involving mealtime insulin.
AI simplified
Key numbers
-1.26%
Reduction (Dulaglutide 1.5 mg)
LS mean reduction at 6 months for men receiving dulaglutide 1.5 mg.
-1.86%
Reduction (Dulaglutide 1.5 mg)
LS mean reduction at 6 months for patients with baseline ≥8.5%.
5470
Total Patients Analyzed
Total number of patients across seven phase III studies.